Apriori Bio
Boston
About Apriori Bio
Apriori Bio is a health security company, aimed at protecting humanity against viral threats. The company uses a unique technology platform that enables the creation of variant-resilient vaccines and provides real-time insights to prepare for future outbreaks. Apriori Bio focuses on designing new vaccines and antibody drugs to combat existing and potential viral variants. With its innovative approach, the company aims to ensure durable protection against rapidly evolving viruses
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $51.1M
- Funding stage: Early Stage Venture
- Last round: Grant (Jul 2024)
- Website: aprioribio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Clinical Trials, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/apriori-bio-92629 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.